- Greek Cabinet Approves EU, IMF Bailout Bill
- We're Not Greece: Italian Prime Minister Monti
- Private Homebuilders in the US: Dead Men Walking
- Dividend Payout Could Hit Record Amount This Year
- With Investors So Bullish, Stock Pullback Must Be Ahead
- Obama Likely to Call for Cutting Top Corporate Tax Rate
- New York Fashion Week Fall 2012
- NetNet: Why Saving Greece Could Destroy the World
- My Funny Valentine: When Love and the Fed Collide
MOST SHARED
- We're Not Greece: Italian Prime Minister Monti
- Obama Likely to Call for Cutting Top Corporate Tax Rate
- To Play Senate Cybersecurity Bill, Cramer Likes Fortinet Stock
- Greek Cabinet Approves EU, IMF Bailout Bill
- Special Feature: Wall Street History - How Wall Street Got Its Name
- How to Trade the Turmoil in Greece
- Private Homebuilders: Dead Men Walking
- Why Cramer Likes Select Comfort Over Tempur-pedic Stock
- Cramer: 10 Earnings to Watch Next Week
- Lightning Round: Trina Solar, Zoltek, Affymax and More
MOST POPULAR
HOT ON FACEBOOK
Lowering Cholesterol May Boost Cancer Risk, Study Says
Text Size 
A new study shows lowering cholesterol could increase the risk of cancer.
The Journal of the American College of Cardiology reports that researchers observed as much as triple the incidence of cancer among patients who lowered their bad or LDL cholesterol using the popular drugs known as statins. The rate, the study says, was especially high among patients with cholesterol levels below 160.
But they don't know if the cancer was caused by the drug, the low cholesterol or happenstance. The doctors who did the study say the heart benefits of statins still outweigh the risk of cancer and that patients should not stop taking their medication.
Researchers looked at the results of clinical trials involving more than 75,000 people who took statins. They're the
biggest segment of the drug industry accounting for $18 billion in sales in 2006, according to Verispan, which monitors prescriptions.
Pfizer's [PFE
Loading...
()
] Lipitor, Merck [MRK
Loading...
()
] and Schering-Plough's [SGP
Loading...
()
] Vytorin and AstraZeneca's [AZN
Loading...
()
] Crestor are among the top-selling brand-name statins.
The editor of JACC says the staff debated for three weeks whether to publish this study, but in the end decided that "these findings could not be ignored, that they did warrant further investigation, and that they should be aired in public."
Pfizer, which makes the world's top-selling statin, Lipitor, called the JACC study limited. The company said similar, larger analyses have shown no increased risk of cancer on the drug and that a company-sponsored clinical trial of 10,000 patients also showed no increased risk of cancer death.
Pfizer also said that the JACC study indicates no causal relationship between statins and cancer.
- Marketing clichés aside, sometimes diamonds are for investing.
- The ‘Fast Money’ traders weigh in on fashion related stocks from apparel to footwear.
- This list of the 10 most active cities for speed traps was compiled by Trapster.com. See if your town is there.
- This Valentine’s Day should prove a love fest for restaurants, as many couples will be dining out.
- Here’s a look at Westminster Kennel Club’s most successful breeds—and how much they cost.
- What kind of homes do celebrity couples share? Here’s our updated list. Take a look.
Data is a real-time snapshot *Data is delayed at least 15 minutes
